Biotechnology Venture Capital Law In Ukraine.

1. Introduction

Biotechnology Venture Capital Law in Ukraine concerns the legal framework governing investments made by venture capital funds, private investors, business angels, investment companies and foreign financial institutions in biotechnology enterprises.

These investments support the development and commercialisation of:

Genetic engineering and genome-editing technologies.

Pharmaceutical research and biotechnology medicines.

Vaccines and immunological products.

Stem-cell and regenerative medicine.

Medical devices and diagnostic technologies.

Agricultural biotechnology and genetically modified organisms.

Synthetic biology and industrial biotechnology.

Artificial intelligence-assisted drug discovery.

Ukraine does not have one comprehensive statute specifically governing biotechnology venture capital. Instead, the subject is regulated through investment legislation, collective investment legislation, company law, intellectual property law, pharmaceutical regulation, tax law and foreign investment rules.

An important distinction is that venture capital investment law and biotechnology product regulation are separate legal fields. An investor may lawfully finance a biotechnology company, but the company must independently comply with applicable scientific, clinical, manufacturing and marketing requirements.

The Cambridge Centre for Business Research's December 2024 report identifies important strengths and weaknesses in Ukraine's venture capital framework. It particularly discusses convertible financing, shareholder agreements, Diia City and the use of foreign corporate structures.

Cambridge Judge Business School+1

 

2. Constitutional and legislative framework

Ukraine's investment framework is based on several important laws.

LegislationRelevance to biotechnology investment
Constitution of UkraineProtection of property and economic activity
Law on Investment Activity 1991General investment principles
Law on the Regime of Foreign Investment 1996Foreign investment protection
Law on Collective Investment Institutions 2012Investment and venture funds
Civil Code of Ukraine 2003Contracts, property and obligations
Law on Limited and Additional Liability Companies 2018Startup ownership and corporate governance
Law on Joint Stock Companies 2022Equity financing and corporate structure
Law on Protection of Rights to Inventions and Utility ModelsPatent protection
Law on MedicinesPharmaceutical development and authorisation
Law on State Regulation of Activities involving Genetic EngineeringGMO-related regulation

The Law on Investment Activity No. 1560-XII establishes the general legal foundation for investment activity in Ukraine. Its consolidated version was updated on 31 October 2025.

WIPO

 

Constitutional protection

The Ukrainian Constitution provides the broader foundation for:

Protection of private property.

Freedom of entrepreneurial activity.

Equality of ownership rights.

Judicial protection of legal rights.

Protection against unlawful state interference.

These principles are relevant when biotechnology investors face unlawful interference with company assets, research facilities, intellectual property or contractual investment rights.

3. Venture capital funds and collective investment institutions

The principal legislation governing investment funds is the Law of Ukraine No. 5080-VI on Collective Investment Institutions (2012).

This legislation establishes the legal framework for creating, operating, managing and terminating collective investment institutions.

A. Types of investment funds

The Ukrainian framework recognises different collective investment structures, including:

Corporate investment funds.

Unit investment funds.

Venture funds operating within the collective investment framework.

A corporate investment fund is established as a joint-stock company and carries out collective investment activity. Its investors hold shares, and their financial risk is generally limited to their investment in those shares.

zakon.rada.gov.ua+1

 

B. Application to biotechnology

A venture fund may invest in:

Pharmaceutical research companies.

Vaccine-development businesses.

Biotechnology laboratories.

Agricultural genetics enterprises.

Medical diagnostic startups.

Companies commercialising patented biological inventions.

For example, a Ukrainian venture fund could invest in a company developing a new vaccine platform. The fund would acquire an appropriate financial or corporate interest, while the biotechnology company would use the proceeds for research, clinical development, regulatory approval and commercialisation.

C. Investor protection

Important investor protections include:

Proper registration and legal constitution of the investment institution.

Compliance with investment fund regulations.

Appropriate management of investment assets.

Accurate accounting and reporting.

Compliance with applicable restrictions on transactions.

Protection against unauthorised disposal of fund assets.

An important practical issue is that Ukraine does not have a fully developed venture capital structure equivalent to the US limited partnership model. This can create difficulties concerning management rights, investor participation and the transfer of interests.

The OECD's 2024 SME Policy Index also identified the absence of a comprehensive, dedicated venture capital framework and restrictions affecting the institutional investor base.

OECD

 

4. Foreign venture capital investment in Ukrainian biotechnology

Foreign investment is important because biotechnology development requires substantial capital, advanced research facilities, international scientific collaboration and access to global pharmaceutical markets.

The principal legislation includes:

Law on the Regime of Foreign Investment (1996).

Foreign investors may invest in Ukraine through:

Acquisition of corporate shares.

Contributions to company capital.

Investment agreements.

Joint ventures.

Acquisition of intellectual property rights.

Financing of biotechnology research.

Participation in collective investment institutions.

The Law on Investment Activity and the Law on the Regime of Foreign Investment provide the general statutory foundation for these activities.

WIPO+1

 

Legal protections for foreign investors

Foreign investors should consider:

1. Property protection: Their investments and acquired property rights receive protection under Ukrainian law.

2. Contractual protection: Investment agreements can establish payment obligations, management arrangements, warranties and dispute-resolution procedures.

3. Intellectual property protection: Patents, trademarks, copyright and trade secrets can form part of the investment structure.

4. Corporate protection: Shareholder agreements and company statutes can establish voting, information and transfer rights.

5. Dispute resolution: Depending on the nature of the dispute and the applicable law, litigation or international arbitration may be available.

However, foreign investors must also consider sanctions, foreign-exchange restrictions, national security considerations and applicable regulatory approvals.

5. Biotechnology startup financing and investment agreements

Investment agreements are central to biotechnology venture capital.

A biotechnology company may require multiple financing rounds because its research may take years to reach commercialisation.

A. Seed financing

Seed investment supports:

Initial laboratory research.

Proof-of-concept experiments.

Early-stage genetic research.

Preliminary patent applications.

Scientific personnel recruitment.

B. Series A financing

Series A funding may support:

Preclinical development.

Clinical research preparation.

Laboratory expansion.

Regulatory consultations.

Manufacturing development.

C. Series B financing

Series B funding may support:

Clinical trials.

Pharmaceutical manufacturing.

Product validation.

International regulatory submissions.

Commercial partnerships.

D. Later-stage financing

Later-stage investment may finance:

Large-scale production.

International distribution.

Pharmaceutical licensing.

Acquisition of biotechnology businesses.

Public offerings or strategic exits.

Important contractual instruments

InstrumentLegal purpose
Share subscription agreementInvestor acquires newly issued shares
Share purchase agreementInvestor purchases existing ownership interests
Shareholder agreementEstablishes investor and founder rights
Convertible loanLoan potentially converted into equity
Licensing agreementAllows commercial use of biotechnology IP
Research collaboration agreementRegulates joint scientific development
Confidentiality agreementProtects confidential scientific information
Due diligence agreementSupports investigation of investment risks

Convertible loans

Convertible financing allows an investor to provide money as a loan that may subsequently convert into equity under agreed conditions.

For example, an investor may finance a Ukrainian biotechnology startup with €500,000. The agreement may provide for conversion into company ownership when the startup completes its next financing round.

The legal difficulty is that the enforceability and implementation of venture-style convertible instruments must be examined against Ukrainian civil and corporate law. The Cambridge 2024 study specifically identifies uncertainty surrounding convertible debt in the wider Ukrainian legal framework.

Accordingly, investors should carefully draft conversion conditions, valuation mechanisms, maturity provisions and corporate approvals.

Cambridge Judge Business School+1

 

6. Diia City and biotechnology venture capital

Diia City is a special legal regime designed to encourage technology businesses and innovation in Ukraine.

It is particularly relevant to biotechnology companies combining biological research with software, artificial intelligence, computational biology and medical technology.

Its investment-related arrangements include:

Convertible loan instruments.

Option agreements.

Non-disclosure agreements.

Non-compete arrangements, subject to statutory conditions.

Representations and warranties.

Special employment and taxation arrangements.

However, Diia City is not an automatic tax or investment regime for every biotechnology business. Eligibility depends on the statutory criteria, including the company's activities and other qualification requirements.

For example:

A biotechnology enterprise developing AI-assisted drug discovery software may qualify if it satisfies the applicable requirements. A traditional pharmaceutical manufacturing business cannot assume that it qualifies merely because it operates in the biotechnology industry.

The Ukrainian investment promotion authority identifies eligible research and development activities in IT and telecommunications as potential beneficiaries of Diia City.

UkraineInvest+1

 

7. Intellectual property protection and biotechnology investment

Intellectual property is one of the most valuable assets of a biotechnology startup.

A venture capital investor will often evaluate the company's patent portfolio before providing funding.

Main intellectual property assets

A. Patents

Patents may protect qualifying inventions involving:

Pharmaceutical compositions.

Biotechnology manufacturing methods.

Diagnostic technologies.

Biological processes.

Medical devices.

Patentability depends on statutory requirements, including novelty, inventive step and industrial applicability, as well as exclusions under applicable law.

B. Trade secrets

Trade secrets can protect:

Laboratory protocols.

Experimental results.

Manufacturing processes.

Biological formulations.

Proprietary research databases.

C. Copyright

Copyright may protect software, research documentation and qualifying original scientific materials, although it does not confer ownership over scientific ideas or discoveries as such.

D. Licensing

A startup may license its biotechnology patent to a pharmaceutical company in return for royalties, milestone payments or other financial benefits.

Importance for venture capital

Investors should investigate:

Who legally owns the patents?

Were inventions created by employees or university researchers?

Were research agreements properly executed?

Are there competing patent claims?

Are international patent applications pending?

Are research materials subject to third-party licensing?

Can the company commercially exploit its inventions?

A failure to establish ownership of core biotechnology inventions can significantly undermine the value of an investment.

8. Important judicial decisions and case laws

Ukraine does not yet have a substantial body of reported judgments specifically concerning venture capital investments in biotechnology startups. Nevertheless, Supreme Court decisions concerning corporate investment, collective investment funds, contractual arrangements and pharmaceutical patents provide important legal principles.

The following cases are particularly relevant.

Case 1. Supreme Court – Case No. 910/7975/21 (18 May 2023)

Relevant investment-law precedent

Court: Commercial Cassation Court of the Supreme Court of Ukraine.

Legal issue: Distinction between an investment agreement and a joint-activity agreement.

Judicial principle:

The Court distinguished an investment agreement, which principally regulates the provision of investment in return for financial or property benefits, from a joint-activity agreement, under which parties combine contributions and efforts to achieve a common objective.

Importance for biotechnology venture capital:

This distinction is important when a pharmaceutical company and a biotechnology investor collaborate on vaccine development.

For example:

An investor provides €1 million to finance research in return for an agreed financial benefit.

A pharmaceutical company and a research institution combine financial resources, scientific expertise and laboratory facilities to achieve a common research objective.

These arrangements may require different contractual structures and legal treatment.

The judgment helps parties avoid incorrectly classifying an investment transaction as a joint venture.

supreme.court.gov.ua

 

Case 2. Supreme Court – Case No. 922/2177/25 (3 September 2026)

Important fund-governance precedent

Court: Commercial Cassation Court of the Supreme Court.

Legal issue: Whether an asset management company could enter into a transaction exceeding its authority without prior supervisory board approval.

Facts and decision:

The asset management agreement restricted transactions involving corporate fund assets above UAH 7 million without prior supervisory board approval.

The disputed assignment of claims concerned UAH 20 million. The transaction was concluded without the required approval.

The Supreme Court upheld the invalidation of the transaction because the asset manager had exceeded its contractual authority and the counterparty knew of the relevant restrictions.

Importance for biotechnology venture capital:

Suppose a venture fund invests in a biotechnology company and its asset manager attempts to transfer valuable patent-related claims without obtaining the approval required by the fund's governing documents.

This judgment demonstrates why investors should establish:

Clear asset-management powers.

Supervisory board approval requirements.

Transaction-value limits.

Internal authorisation procedures.

Protection against unauthorised transfers.

The case is particularly significant for governance of corporate investment funds.

КГС ВС

 

Case 3. Supreme Court – Case No. 910/9215/21 (27 April 2023)

Court: Commercial Cassation Court of the Supreme Court.

Subject: Pharmaceutical patent protection and medicinal product registration.

Legal issue: Whether steps taken to obtain marketing authorisation for a medicinal product could infringe an existing patent.

Judicial significance:

The Court considered patent protection in relation to the preparation of a pharmaceutical product for introduction into civil circulation.

The judgment is relevant because biotechnology businesses frequently develop patented pharmaceutical compositions and biological medicines.

Importance for investors:

Before investing in a pharmaceutical biotechnology startup, the investor should investigate whether:

The company owns the relevant patent.

A competitor holds conflicting patent rights.

Regulatory registration activities create infringement risks.

The proposed product can legally enter the market.

The decision is especially relevant to pharmaceutical investment due diligence.

Chambers and Partners+1

 

Case 4. Supreme Court – Case No. 910/9528/25 (30 April 2026)

Subject: Supplementary protection of a pharmaceutical patent.

Legal issue: Whether patent rights remained effective during martial law and whether supplementary protection could be obtained.

Facts and judicial findings:

The dispute concerned Ukrainian Patent No. 85536, relating to an active pharmaceutical ingredient used in a medicinal product.

The patent's ordinary expiry date fell during martial law. The Supreme Court upheld the lower courts' conclusion that the relevant legislation preserved the proprietary intellectual property rights during martial law and that supplementary protection was available in the circumstances.

Importance for biotechnology venture capital:

Patent duration directly affects the potential commercial value of biotechnology investments.

An investor financing vaccine or pharmaceutical research should consider:

Remaining patent protection.

Supplementary protection eligibility.

Patent expiry risks.

Commercial exclusivity.

Regulatory approval timelines.

The decision is particularly relevant to the valuation of pharmaceutical biotechnology portfolios.

court.gov.ua

 

Case 5. Supreme Court – Amstor LLC dispute (17 December 2020)

Subject: Rights of an LLC member challenging a transaction entered into by the company.

Legal issue: Whether a shareholder or LLC participant can challenge a company's commercial transaction merely because they believe their corporate interests were affected.

Judicial principle:

The Supreme Court upheld the dismissal of the member's claim in the circumstances of the case. The decision considered the distinction between the company's contractual rights and the individual corporate rights of its members.

Importance for biotechnology investment:

A minority investor in a biotechnology company cannot assume that every disputed company transaction automatically gives them a personal right to invalidate it.

Investment agreements should therefore clearly establish:

Reserved matters.

Voting rights.

Information rights.

Approval requirements.

Remedies for breaches of investor protections.

court.gov.ua

Case 6. Grand Chamber of the Supreme Court – Case No. 904/10956/16

Subject: Corporate approval and transactions concluded by company executives.

Legal principle:

The Grand Chamber explained that a company's executive entering into a transaction without the required internal approval may primarily affect the company's rights and interests, rather than automatically creating a personal corporate claim for every shareholder.

It also discussed alternative mechanisms for protecting corporate rights, including company action and claims against officers in appropriate circumstances.

Importance for biotechnology investment:

A biotechnology startup may enter into expensive research, licensing or laboratory acquisition agreements.

Investors should ensure that its articles of association and corporate agreements clearly identify which transactions require investor or supervisory approval.

supreme.court.gov.ua

Case 7. Supreme Court – 30 September 2025

Subject: Arbitration of a share purchase dispute.

Judicial principle:

The Supreme Court explained that a claim for the transfer of shares under a share purchase agreement may be arbitrable under an applicable arbitration clause, where the dispute is contractual rather than a dispute concerning the company's establishment, management or termination.

Importance for biotechnology investors:

Foreign investors may negotiate arbitration provisions for share purchase and investment agreements. However, the nature of the dispute and statutory jurisdictional restrictions must be examined before selecting arbitration.

court.gov.ua+1

Overall case-law observation: These judgments are analogous authorities relevant to biotechnology venture capital. They should not be misrepresented as cases directly deciding the legality of a biotechnology venture capital investment.

9. Biotechnology regulatory compliance and investor responsibility

Venture capital investment does not exempt biotechnology companies from regulatory requirements.

Investors should assess the following areas.

Regulatory areaPrincipal legal concern
Pharmaceutical productsAuthorisation and quality requirements
Clinical trialsEthical approval and participant protection
Genetic engineeringGMO-related regulatory compliance
Biological materialsLawful acquisition, use and transfer
Human genetic dataPrivacy and data protection
Laboratory operationsBiosafety and applicable licensing
Medical devicesApplicable conformity and market requirements
Research institutionsResearch ethics and intellectual property ownership

Clinical trial investment

A venture fund financing a clinical-stage biotechnology company should examine:

Clinical trial authorisations.

Ethics committee approvals.

Informed consent documentation.

Clinical trial insurance and liability.

Data integrity.

Adverse-event reporting.

Good Clinical Practice compliance.

A failure in clinical trial compliance may result in delays, financial losses, regulatory action and contractual disputes.

Genetic data protection

Biotechnology startups frequently process sensitive personal information, including genetic and health data.

Investors should examine compliance with Ukraine's Law on Personal Data Protection and any applicable international data protection requirements.

For cross-border biotechnology enterprises, the legal implications of transferring patient information and genomic datasets must also be considered.

10. Taxation of biotechnology venture capital

Tax treatment is an important part of investment structuring.

Relevant issues include:

Corporate income taxation.

Tax treatment of dividends.

Taxation of capital gains.

Withholding taxes on cross-border payments.

Tax treatment of royalties.

Research and development expenditure.

Transfer pricing.

Applicable international tax treaties.

Venture capital fund structures may offer specific tax advantages under Ukrainian collective investment legislation. However, the availability of a tax advantage depends on the fund's legal structure, transactions and applicable statutory requirements.

Diia City residents may also qualify for special tax treatment if they meet the statutory conditions.

Investors must distinguish between a biotechnology company's tax status and the tax status of the fund financing it.

11. Recent legislative developments and proposed reforms (2025–2026)

Ukraine is working towards modernising its investment and capital-market framework.

A. Proposed Law on Investment Funds – October 2026

On 9 October 2026, the National Securities and Stock Market Commission announced that a draft Law on Investment Funds had been submitted to Parliament for registration.

The proposed reform seeks to:

Introduce public and alternative investment funds.

Modernise investment fund management.

Improve transparency and disclosure.

Strengthen investor protection.

Create a framework for venture capital funds.

Align Ukrainian legislation with European Union investment standards.

The proposal draws on European legislation, including:

Directive 2009/65/EC (UCITS).

Directive 2011/61/EU (AIFMD).

Regulation (EU) No. 345/2013 (EuVECA).

Regulation (EU) No. 346/2013 (EuSEF).

Regulation (EU) 2015/760 (ELTIF).

Legal significance: This is a proposed reform, not legislation that should be treated as already enacted. Its eventual adoption could significantly affect the legal environment for biotechnology venture capital.

nssmc.gov.ua

 

B. Corporate law reform – 2025

Law No. 4564-IX, signed on 26 August 2025, introduced changes to the legal framework for limited and additional liability companies.

The amendments provide for additional capital contributions without necessarily changing the company's registered charter capital or the nominal value of existing participants' shares.

Such contributions may involve money, securities or other property.

Biotechnology significance: This can offer another way to finance biotechnology enterprises while maintaining the existing nominal ownership structure, subject to the company's constitutional documents and statutory requirements.

August 2025

 

12. Major legal challenges facing biotechnology venture capital in Ukraine

The following challenges deserve particular attention.

ChallengePotential legal consequence
Uncertain convertible financing rulesConversion disputes
Corporate governance weaknessesInvestor control disputes
Patent ownership conflictsLoss of commercialisation rights
Clinical trial failuresFinancial and regulatory liability
Unclear university IP ownershipResearch ownership disputes
War-related risksAsset destruction and business interruption
Foreign-exchange restrictionsDifficulties repatriating investment returns
Cross-border data restrictionsResearch and privacy compliance problems
Inadequate fund structuresInvestor protection difficulties
Regulatory uncertaintyDelayed investment returns

The impact of the Russia–Ukraine war

The ongoing war creates additional legal and commercial risks for biotechnology investment.

These include:

Destruction of laboratories and research infrastructure.

Disruption of clinical trials.

Loss of biological samples.

Interrupted pharmaceutical supply chains.

Insurance and force majeure disputes.

Difficulties transferring capital internationally.

Security risks affecting research personnel.

Investors should therefore consider business continuity provisions, insurance arrangements, alternative laboratory facilities, secure data backups and contractual allocation of extraordinary risks.

13. Practical example: Venture capital investment in a Ukrainian vaccine startup

Consider a hypothetical Ukrainian biotechnology company developing an innovative vaccine.

Illustrative investment structure

€5 million

Total hypothetical venture capital commitment

Venture capital fund

Provides financing under an investment agreement.

Biotechnology startup

Receives funding and undertakes vaccine research.

Research institution

Conducts laboratory experiments under a research collaboration agreement.

Intellectual property protection

The startup secures appropriate patent and trade-secret rights.

Clinical development

The company obtains the required regulatory and ethical approvals.

Commercialisation

The company enters licensing, manufacturing and distribution arrangements.

Possible investment allocation

PurposeAmount
Laboratory research€1 million
Preclinical development€1 million
Clinical development€1.5 million
Manufacturing development€1 million
Legal and regulatory compliance€0.5 million
Total€5 million

Illustrative figures only, not actual Ukrainian investment data.

The fund's investment agreement should address milestone-based financing, intellectual property ownership, founder obligations, regulatory compliance, investor voting rights, liquidation preferences where legally enforceable, and exit mechanisms.

This structure demonstrates how investment law, corporate governance, pharmaceutical regulation and intellectual property law operate together.

14. Recommendations for strengthening Ukrainian biotechnology venture capital law

Several reforms could improve the investment environment.

1. Dedicated biotechnology investment framework

Ukraine could develop clearer statutory guidance for investments in pharmaceutical research, genetic engineering and advanced biological technologies.

2. Improved convertible financing rules

Clearer rules governing convertible loans, conversion events and investor rights would reduce contractual uncertainty.

3. Stronger corporate governance

Investor approval rights, disclosure obligations and supervisory mechanisms should be clearly recognised and enforceable.

4. University research commercialisation

Universities should establish transparent rules governing patent ownership, technology licensing and researcher participation in biotechnology startups.

5. Stronger intellectual property protection

Biotechnology investors need predictable patent enforcement and reliable protection of confidential scientific information.

6. International cooperation

Alignment with European biotechnology, investment and pharmaceutical standards can improve access to international investors.

7. Research and development incentives

Targeted incentives could encourage investment in vaccine development, agricultural biotechnology, medical research and pharmaceutical manufacturing.

15. Conclusion

Biotechnology venture capital law in Ukraine is an evolving area of investment and corporate regulation. It does not operate through a single dedicated biotechnology venture capital statute. Instead, it combines the Law on Investment Activity, the Law on Foreign Investment, the Law on Collective Investment Institutions, corporate legislation, intellectual property protection and biotechnology regulatory requirements.

The Ukrainian Supreme Court's decisions on investment agreements, fund-management authority, shareholder rights, pharmaceutical patents and arbitration provide important principles for structuring and protecting biotechnology investments.

The proposed investment fund reforms announced in October 2026 may represent an important development towards a more European-style investment framework.

Ultimately, the development of biotechnology venture capital in Ukraine depends on three interconnected factors:

Predictable and enforceable investment agreements.

Effective protection of biotechnology intellectual property.

Reliable corporate governance and regulatory institutions.

A stable legal framework could help Ukraine attract domestic and international venture capital for pharmaceutical innovation, vaccine research, genetic engineering, medical technology and other advanced biotechnology industries.

16. Important legal research sources

For academic research, dissertation writing and further case-law investigation, the following primary and institutional resources are useful:

Law on Investment Activity – WIPO Lex.

Law on the Regime of Foreign Investment – UNCTAD.

Law on Collective Investment Institutions – Ukrainian legislation.

Cambridge Report: The Legal Framework for Venture Capital in Ukraine (2024).

Proposed Law on Investment Funds – NSSMC (2026).

Supreme Court decision – Case No. 910/7975/21.

Supreme Court decision – Case No. 922/2177/25.

Supreme Court decision – Case No. 910/9528/25.

Academic qualification: The case-law discussed above includes analogous corporate, investment-fund and pharmaceutical patent decisions. It should not be presented as a collection of direct biotechnology venture capital judgments. For legal proceedings, the original Ukrainian judgments and legislation in force on the relevant transaction date should be checked.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT